For research use only. Not for therapeutic Use.
EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants[1].
EMI48 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI48 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].
| Catalog Number | I015151 |
| CAS Number | 34564-13-1 |
| Synonyms | 7-(diethylamino)-3-(5-methyl-1,3-benzoxazol-2-yl)chromen-2-one |
| Molecular Formula | C21H20N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H20N2O3/c1-4-23(5-2)15-8-7-14-11-16(21(24)26-19(14)12-15)20-22-17-10-13(3)6-9-18(17)25-20/h6-12H,4-5H2,1-3H3 |
| InChIKey | PTAGJQADNFQMGR-UHFFFAOYSA-N |
| SMILES | CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C3=NC4=C(O3)C=CC(=C4)C |
| Reference | [1]. Punit Saraon , et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586. |
